Compare BBCP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | RLMD |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.0M | 319.0M |
| IPO Year | 2017 | N/A |
| Metric | BBCP | RLMD |
|---|---|---|
| Price | $6.43 | $3.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $9.00 |
| AVG Volume (30 Days) | 139.3K | ★ 568.7K |
| Earning Date | 03-10-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $392,867,000.00 | N/A |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $72.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.78 | $0.24 |
| 52 Week High | $8.05 | $5.12 |
| Indicator | BBCP | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 42.66 |
| Support Level | $5.89 | $3.22 |
| Resistance Level | $6.32 | $3.93 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 94.77 | 33.42 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.